Hostname: page-component-cd9895bd7-8ctnn Total loading time: 0 Render date: 2024-12-22T23:33:42.708Z Has data issue: false hasContentIssue false
  • English
  • Français

Effects of add-on tipepidine on treatment-resistant depression: an open-label pilot trial

Published online by Cambridge University Press:  20 July 2015

Yukihiko Shirayama ,
Masatoshi Suzuki ,
Michio Takahashi ,
Koichi Sato  and
Kenji Hashimoto
Yukihiko Shirayama*
Affiliation:
Department of Psychiatry, Teikyo University Chiba Medical Center, Ichihara, Japan
Masatoshi Suzuki
Affiliation:
Department of Psychiatry, Teikyo University Chiba Medical Center, Ichihara, Japan
Michio Takahashi
Affiliation:
Department of Psychiatry, Teikyo University Chiba Medical Center, Ichihara, Japan
Koichi Sato
Affiliation:
Department of Psychiatry, Teikyo University Chiba Medical Center, Ichihara, Japan
Kenji Hashimoto
Affiliation:
Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, Chiba, Japan
*
Yukihiko Shirayama, Department of Psychiatry, Teikyo University Chiba Medical Center, 3426-3 Anesaki, Ichihara 299-0111, Japan. Tel: +8 143 662 1211; Fax: +8 143 662 1511; E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective

Treatment-resistant depression is a challenging problem in the clinical setting. Tipepidine has been used as a non-narcotic antitussive in Japan since 1959.

Methods

We administered tipepidine to 11 patients with treatment-resistant depression. Tipepidine was given for 8 weeks as an augmentation.

Results

Tipepidine significantly improved depression scores on the Hamilton Rating Scale for depression. Add-on treatment with tipepidine significantly improved scores on the trail making test and Rey auditory verbal learning test. However, no changes were observed in blood concentrations of stress-related hormones (adrenocorticotropic hormone, cortisol, dehydroepiandrosterone sulphate) with tipepidine augmentation.

Conclusion

Tipepidine might be a potential therapeutic drug for treatment-resistant depression.

Keywords

tipepidinetreatment-resistant depressionverbal learning
Type
Short Communications
Information
Acta Neuropsychiatrica , Volume 28 , Issue 1 , February 2016 , pp. 51 - 54
Check for updates
Copyright
© Scandinavian College of Neuropsychopharmacology 2015 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Souery, D, Amsterdam, J, de Montigny, C et al. Treatment resistant depression: methodological overview and operational criteria. Euro Neuropsychopharmacol 1999;9:83–91.Google Scholar
2. Nemeroff, CB. Prevalence and management of treatment-resistant depression. J Clin Psychiatry 2007;68(Suppl. 8):17–25.Google Scholar
3. Thase, ME, Rush, AJ. Treatment-resistant depression. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: the fourth generation of progress. USA: Raven Press, 1995. p. 1081–1097.Google Scholar
4. Schosser, A, Serretti, A, Souery, D et al. European group for the study of resistant depression (GSRD) – where have we gone so far: review of clinical and genetic findings. Euro Neuropsychopharmacol 2012;22:453–468.Google Scholar
5. Ruhé, HG, Van Rooijen, G, Spijker, J, Peeters, FP, Schene, AH. Staging methods for treatment resistant depression. A systematic review. J Affect Disord 2012;137:35–45.Google Scholar
6. Thase, ME. Evaluating antidepressant therapies: remission as the optimal outcome. J Clin Psychiatry 2003;64(Suppl. 13):18–25.Google ScholarPubMed
7. Fava, GA, Ruini, C, Belaise, C. The concept of recovery in major depression. Psychol Med 2007;37:307–317.Google Scholar
8. Sasaki, T, Hashimoto, K, Tachibana, M et al. Tipepidine in adolescent patients with depression: a 4 week, open-label, preliminary study. Neuropsychiatr Dis Treat 2014;10:719–722.CrossRefGoogle ScholarPubMed
9. Kawaura, K, Ogata, Y, Inoue, M et al. The centrally acting non-narcotic antitussive tipepidine produces antidepressant-like effect in the forced swimming test in rats. Behav Brain Res 2009;205:315–318.CrossRefGoogle ScholarPubMed
10. Kawaura, K, Miki, R, Urashima, Y et al. Pharmacological mechanisms of antidepressant-like effect of tipepidine in the forced swimming test. Behav Brain Res 2012;226:381–385.Google Scholar
11. Kawahara, R, Soeda, F, Kawaura, K et al. Effects of tipepidine with novel antidepressant-like action on c-fos-like protein expression in rat brain. Brain Res 2013;1513:135–142.CrossRefGoogle ScholarPubMed
12. Hamasaki, R, Shirasaki, T, Soeda, F, Takahama, K. Tipepidine activates VTA dopamine neuron via inhibiting dopamine D2 receptor-mediated inward rectifying K+ current. Neuroscience 2013;252:24–34.Google Scholar
13. Takebayashi, M, Kagaya, A, Uchitomi, Y et al. Plasma dehydroepiandrosterone sulfate in unipolar major depression. J Neural Transm 1998;105:537–542.CrossRefGoogle ScholarPubMed
14. Maayan, R, Yagorowski, Y, Grupper, D et al. Basal plasma dehydroepiandrosterone sulfate level: a possible predictor for response to electroconvulsive therapy in depressed psychotic inpatients. Biol Psychiatry 2000;48:693–701.CrossRefGoogle Scholar
15. Young, AH, Gallgher, P, Porter, RJ. Elevation of the cortisol-dehydroepiandrosterone ratio in drug-free depressed patients. Am J Psychiatry 2002;159:1237–1239.Google Scholar
16. Markopoulou, K, Papadopoulos, A, Juruena, MF, Poon, L, Pariante, CM, Cleare, AJ. The ratio of cortisol/DHEA in treatment resistant depression. Psychoneuroendocrinology 2009;34:19–26.Google Scholar
17. Hinkelmann, K, Moritz, S, Botzenhardt, J et al. Cognitive impairment in major depression: association with salivary cortisol. Biol Psychiatry 2009;66:879–885.CrossRefGoogle ScholarPubMed
18. Juruena, MF, Pariante, CM, Papadopoulos, AS, Poon, L, Lightmans, S, Cleare, AJ. Prednisolone suppression test in depression: prospective study of the role of HPA axis dysfunction in treatment resistance. Br J Psychiatry 2009;194:342–349.CrossRefGoogle ScholarPubMed
19. Michael, A, Jenaway, A, Paykel, ES, Herbert, J. Altered salivary dehydroepiandrosterone levels in major depression in adults. Biol Psychiatry 2000;48:989–995.Google Scholar
20. Douglas, KM, Porter, RJ, Knight, KG, Maruff, P. Neuropsychological changes and treatment response in severe depression. Br J Psychiatry 2011;198:115–122.Google Scholar
21. Egeland, J, Lund, A, Landro, NI et al. Cortisol level predicts executive and memory function in depression, symptom level predicts psychomotor speed. Acta Psychiatr Scand 2005;112:434–441.CrossRefGoogle ScholarPubMed
22. American Psychiatric Association. Diagnostic and Statistic Manual of Mental Disorders (4th edn., text rev) Washington, DC: American Psychiatric Press, 1994.Google Scholar
23. Hamao, K, Kawaura, K, Soeda, F, Hamasaki, R, Shirasaki, T, Takahama, K. Tipepidine increase dopamine level in the nucleus accumbens without methamphetamine-like behavioral sensitization. Behav Brain Res 2015;284:118–124.CrossRefGoogle ScholarPubMed
24. Kitamura, Y, Yagi, T, Kitagawa, K et al. Effects of bupuropion on the forced swim test and release of dopamine in the nucleus accumbens in ACTH-treated rats. Naunyn Schmiedebergs Arch Pharmacol 2010;382:151–158.CrossRefGoogle ScholarPubMed
25. Bewernick, BH, Hurlemann, R, Matusch, A et al. Nucleus accumbens deep brain stimulation decreases ratings of depression and anxiety in treatment-resistant depression. Biol Psychiatry 2010;67:110–116.CrossRefGoogle ScholarPubMed